Analyst Ratings For Cidara Therapeutics (NASDAQ:CDTX)
Today, Cantor Fitzgerald reiterated its Buy rating on Cidara Therapeutics (NASDAQ:CDTX) with a price target of $15.00.
Some recent analyst ratings include
- 1/19/2018-Cantor Fitzgerald Reiterated Rating of Buy.
- 8/11/2017-WBB Securities Upgrade from a “Sell ” rating to a ” Hold” rating.
- 5/16/2017-Wedbush Reiterated Rating of Outperform.
- 4/29/2017-BTIG Research Reiterated Rating of Buy.
- 4/20/2017-Raymond James Financial initiated coverage with a Strong-Buy rating.
- 4/12/2017-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.
Recent Insider Trading Activity For Cidara Therapeutics (NASDAQ:CDTX)
Cidara Therapeutics (NASDAQ:CDTX) has insider ownership of 18.90% and institutional ownership of 55.45%.
- On 11/15/2017 Target N V Biotech, Major Shareholder, bought 60,000 with an average share price of $7.57 per share and the total transaction amounting to $454,200.00.
- On 9/12/2017 Jeffrey Stein, CEO, bought 7,350 with an average share price of $6.79 per share and the total transaction amounting to $49,906.50.
- On 6/7/2017 Taylor Sandison, Insider, bought 20,000 with an average share price of $5.90 per share and the total transaction amounting to $118,000.00.
- On 6/5/2017 Jeffrey Stein, CEO, bought 15,000 with an average share price of $5.95 per share and the total transaction amounting to $89,250.00.
- On 3/31/2017 Jeffrey Stein, CEO, bought 12,900 with an average share price of $7.75 per share and the total transaction amounting to $99,975.00.
- On 3/31/2017 Kevin Forrest, Insider, bought 12,500 with an average share price of $7.75 per share and the total transaction amounting to $96,875.00.
- On 5/20/2016 Jeffrey Stein, CEO, bought 4,310 with an average share price of $11.51 per share and the total transaction amounting to $49,608.10.
Recent Trading Activity for Cidara Therapeutics (NASDAQ:CDTX)
Shares of Cidara Therapeutics closed the previous trading session at with 7.25 shares trading hands.
